Dynavax(DVAX) - 2025 Q2 - Quarterly Results

Exhibit 99.1 Dynavax Reports Second Quarter 2025 Financial Results EMERYVILLE, CA – August 7, 2025 – Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial- stage biopharmaceutical company developing and commercializing innovative vaccines, today reported financial results and provided a business update for the quarter ended June 30, 2025. "In the second quarter of 2025, we continued our momentum by delivering robust Q2 results, achieving our highest net product revenue quarter ever for HEPLISAV-B, w ...